MA25352A1 - Nouvelle methode de traitement - Google Patents

Nouvelle methode de traitement

Info

Publication number
MA25352A1
MA25352A1 MA26356A MA26356A MA25352A1 MA 25352 A1 MA25352 A1 MA 25352A1 MA 26356 A MA26356 A MA 26356A MA 26356 A MA26356 A MA 26356A MA 25352 A1 MA25352 A1 MA 25352A1
Authority
MA
Morocco
Prior art keywords
processing method
new processing
new
processing
Prior art date
Application number
MA26356A
Other languages
English (en)
Inventor
Creighton P Conley
John A Roush
Kevin H Storm
Original Assignee
Beecham Pharm Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27383840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA25352(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beecham Pharm Pte Ltd filed Critical Beecham Pharm Pte Ltd
Publication of MA25352A1 publication Critical patent/MA25352A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
MA26356A 1999-04-13 2001-10-12 Nouvelle methode de traitement MA25352A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12907499P 1999-04-13 1999-04-13
US15072799P 1999-08-25 1999-08-25
US15981399P 1999-10-15 1999-10-15

Publications (1)

Publication Number Publication Date
MA25352A1 true MA25352A1 (fr) 2001-12-31

Family

ID=27383840

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26356A MA25352A1 (fr) 1999-04-13 2001-10-12 Nouvelle methode de traitement

Country Status (45)

Country Link
EP (4) EP1270005A3 (fr)
JP (2) JP4880125B2 (fr)
KR (1) KR100634937B1 (fr)
CN (1) CN100382782C (fr)
AP (1) AP1806A (fr)
AR (1) AR031068A1 (fr)
AT (2) AT4327U1 (fr)
AU (1) AU767177B2 (fr)
BE (2) BE1012733A6 (fr)
BG (1) BG65006B1 (fr)
BR (1) BRPI0009719B8 (fr)
CA (1) CA2366304C (fr)
CO (1) CO5170471A1 (fr)
CZ (1) CZ298801B6 (fr)
DE (3) DE20006626U1 (fr)
DK (3) DK1044680T3 (fr)
DZ (1) DZ3150A1 (fr)
EA (1) EA004310B1 (fr)
ES (2) ES2202004T3 (fr)
FI (2) FI4823U1 (fr)
FR (1) FR2792198A1 (fr)
GB (1) GB2351661B (fr)
GR (1) GR1003560B (fr)
HK (1) HK1032741A1 (fr)
HU (1) HU229097B1 (fr)
IE (1) IE20000271A1 (fr)
IL (2) IL145580A0 (fr)
IT (1) ITMI20000788A1 (fr)
MA (1) MA25352A1 (fr)
MX (1) MXPA01010377A (fr)
MY (1) MY119953A (fr)
NL (2) NL1014915C2 (fr)
NO (1) NO329694B1 (fr)
NZ (1) NZ514575A (fr)
OA (1) OA11926A (fr)
PE (1) PE20010053A1 (fr)
PL (1) PL197448B1 (fr)
PT (2) PT102450B (fr)
RO (1) RO120817B1 (fr)
SE (1) SE0001330L (fr)
SI (2) SI20304A (fr)
SK (1) SK285140B6 (fr)
TR (1) TR200102963T2 (fr)
TW (1) TWI235067B (fr)
WO (1) WO2000061116A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
NZ318282A (en) 1995-09-07 2000-01-28 Smithkline Beecham Corp Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
EP1330236A2 (fr) 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Nouvelle formulation
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
CN1268338C (zh) 2001-07-06 2006-08-09 恩德制药公司 用作止痛剂的6－羟基羟吗啡酮的口服给药
GB0117618D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
ATE419840T1 (de) 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
JP2005528383A (ja) * 2002-04-10 2005-09-22 ミラー，フレッド，エイチ． 多重相・複数コンパートメントカプセルシステム
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
US8062672B2 (en) 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
EP1541129A1 (fr) * 2003-12-12 2005-06-15 Cimex AG Composition effervescente pharmaceutique contenant de l'amoxicilline et du clavulanate
WO2005079752A2 (fr) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Compositions pharmaceutiques a liberation controlee presentant une meilleure biodisponibilite
WO2005099672A1 (fr) * 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited Formulation pharmaceutique a liberation modifiee contenant de l'amoxicilline et du clavulanate
EP1880716A1 (fr) * 2006-07-19 2008-01-23 Sandoz AG Kit comprenant un produit actif métastable à l'acide et un produit actif stable à l'acide
AU2006349402A1 (en) * 2006-10-10 2008-04-17 Penwest Pharmaceuticals Co. Robust sustained release formulations
TR200909787A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar.
TR201000687A1 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
TR201000686A1 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
AU2016246583B2 (en) * 2015-04-07 2020-06-25 Church & Dwight Co., Inc. Multicomponent gummy compositions with soft core
CN109394718B (zh) * 2018-11-15 2021-04-27 石药集团中诺药业（石家庄）有限公司 一种阿莫西林分散片及其制备方法
CN110051637A (zh) * 2019-05-21 2019-07-26 葵花药业集团北京药物研究院有限公司 阿莫西林克拉维酸钾制剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008905B1 (fr) * 1978-09-06 1983-02-16 Beecham Group Plc Compositions pharmaceutiques contenant deux dérivés de bêta-lactame
IL58461A0 (en) * 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a clavulanic acid salt
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
GB9007945D0 (en) * 1990-04-07 1990-06-06 Beecham Group Plc Pharmaceutical formulation
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
EP1034784A3 (fr) * 1993-01-22 2001-06-27 Smithkline Beecham Plc Formulations pharmaceutique contenant d'acide clavulanique et un agent antibacterien
GB9311030D0 (en) * 1993-05-28 1993-07-14 Smithkline Beecham Corp Pharmaceutical formulations
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
ITMI941169A1 (it) * 1994-06-06 1995-12-06 Smithkline Beecham Farma Formulazioni farmaceutiche
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9416599D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
NZ318282A (en) * 1995-09-07 2000-01-28 Smithkline Beecham Corp Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
GB9616536D0 (en) * 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
TR199901961T2 (xx) * 1997-02-14 1999-11-22 Smith Kline Beecham Laboratoires Pharmaceutiques Amoksosilin ve klav�lanat i�eren ispen�iyariler.
CA2283467A1 (fr) * 1997-03-11 1998-09-17 Almag Al Procede et appareil pour le revetement de metaux
SE9700885D0 (sv) * 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
WO1998042311A1 (fr) * 1997-03-25 1998-10-01 Takeda Chemical Industries, Ltd. Composition pharmaceutique adherant a la muqueuse gastro-intestinale
JP3746901B2 (ja) * 1997-10-15 2006-02-22 ユニ・チャーム株式会社 開閉自在容器
GB9815532D0 (en) * 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
GB9818927D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Pharmaceutical formulation
US6225304B1 (en) * 1999-02-17 2001-05-01 Pharmaceutical Solutions, Inc. Soluble forms of amoxicillin and treatment of animals

Also Published As

Publication number Publication date
BE1013309A5 (fr) 2001-11-06
HU229097B1 (en) 2013-07-29
ES2202004T3 (es) 2004-04-01
HUP0001471A2 (en) 2001-03-28
RO120817B1 (ro) 2006-08-30
EA200101075A1 (ru) 2002-04-25
AP1806A (en) 2007-12-14
BG65006B1 (bg) 2006-12-29
AU5702000A (en) 2000-11-14
FI20000863A (fi) 2000-10-13
BR0009719B1 (pt) 2014-09-30
FI4823U1 (fi) 2001-02-16
NO20001870D0 (no) 2000-04-11
ES2190692A1 (es) 2003-08-01
NO329694B1 (no) 2010-12-06
DK200000602A (da) 2000-10-14
ATE242629T1 (de) 2003-06-15
WO2000061116A2 (fr) 2000-10-19
NL1014914C1 (nl) 2000-10-16
EP1044680A1 (fr) 2000-10-18
IL145580A0 (en) 2002-11-10
ES2190692B1 (es) 2004-11-16
AU767177B2 (en) 2003-11-06
SK5342000A3 (en) 2000-11-07
DE60003255D1 (de) 2003-07-17
ITMI20000788A0 (it) 2000-04-11
JP2011256180A (ja) 2011-12-22
FI20000863A0 (fi) 2000-04-11
CA2366304C (fr) 2004-06-29
NO20001870L (no) 2000-10-16
PT102450A (pt) 2001-02-01
BG104329A (en) 2001-11-30
HK1032741A1 (en) 2001-08-03
SI1044680T1 (en) 2003-12-31
CO5170471A1 (es) 2002-06-27
PL197448B1 (pl) 2008-03-31
SK285140B6 (sk) 2006-07-07
DE20006626U1 (de) 2000-10-19
TR200102963T2 (tr) 2002-02-21
DZ3150A1 (fr) 2000-10-19
PL339591A1 (en) 2000-10-23
BR0009719A (pt) 2002-01-08
JP2002541187A (ja) 2002-12-03
DE60003255T2 (de) 2004-05-06
EP1044680B1 (fr) 2003-06-11
BRPI0009719B8 (pt) 2021-05-25
CZ20001311A3 (cs) 2000-11-15
BE1012733A6 (fr) 2001-02-06
OA11926A (en) 2006-04-12
FIU20000164U0 (fi) 2000-04-11
KR20020015312A (ko) 2002-02-27
CN100382782C (zh) 2008-04-23
IL145580A (en) 2007-05-15
EA004310B1 (ru) 2004-02-26
CA2366304A1 (fr) 2000-10-19
EP1269997A1 (fr) 2003-01-02
GB0008923D0 (en) 2000-05-31
IE20000271A1 (en) 2001-04-04
DK1044680T3 (da) 2003-09-29
SI20304A (sl) 2001-02-28
CZ298801B6 (cs) 2008-02-06
SE0001330L (sv) 2000-10-14
FR2792198A1 (fr) 2000-10-20
HU0001471D0 (en) 2000-06-28
TWI235067B (en) 2005-07-01
NL1014915A1 (nl) 2000-10-16
PT1044680E (pt) 2003-10-31
WO2000061116A3 (fr) 2001-02-01
GB2351661A (en) 2001-01-10
SE0001330D0 (sv) 2000-04-11
CN1382040A (zh) 2002-11-27
EP1270005A3 (fr) 2006-05-17
GB2351661B (en) 2001-10-10
GR1003560B (el) 2001-03-16
KR100634937B1 (ko) 2006-10-17
PT102450B (pt) 2003-09-30
NL1014915C2 (nl) 2001-02-12
AP2001002284A0 (en) 2001-12-31
PE20010053A1 (es) 2001-03-10
DK200000133U3 (da) 2000-07-28
ITMI20000788A1 (it) 2001-10-11
MY119953A (en) 2005-08-30
EP1270005A2 (fr) 2003-01-02
HUP0001471A3 (en) 2001-10-29
DE10017883A1 (de) 2000-10-26
EP1269996A1 (fr) 2003-01-02
AR031068A1 (es) 2003-09-10
MXPA01010377A (es) 2002-10-23
AT4327U1 (de) 2001-06-25
JP4880125B2 (ja) 2012-02-22
NZ514575A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
MA25352A1 (fr) Nouvelle methode de traitement
MA25351A1 (fr) Nouvelle methode de traitement
FR2814945B1 (fr) Procede de traitement de la canitie
LU93315I2 (fr) Procédé de traitement de la sclérose multiple - daclizumab
DE10084419T1 (de) Automatisierte Prozesslinien
DE60034915D1 (de) Synchrones Datenverarbeitungsverfahren
DE60028075D1 (de) Bildverarbeitungsgerät
DE69928835D1 (de) Farbverarbeitung
DE60022860D1 (de) Waferbearbeitungssystem
DE60030210D1 (de) Elektrolytisches Behandlungsverfahren
DE60313090D1 (de) Bearbeitungssystem
DE60138995D1 (de) Betrugssicheres Verarbeitungsverfahren
DE60215096D1 (de) Optisches Verarbeitungssystem
FR2788234B1 (fr) Procede de chanfreinage
DE60033589D1 (de) Bildverarbeitung
PT1278816E (pt) Metodo para processar azeitonas
DE60213924D1 (de) Bildverarbeitungsverfahren
DE69905294D1 (de) Bildverarbeitung
MA25522A1 (fr) Procede de traitement de copd
DE10194962T1 (de) Bildverarbeitungsverfahren
DE60005700D1 (de) Fadenverarbeitungssystem
DE60005362D1 (de) Programmübersichtsverarbeitung
FI20002692A (fi) Tiedonkäsittelymenetelmä
DE60044370D1 (de) Bildverarbeitungsgerät
FR2792659B1 (fr) Procede de nettoyage de vetements contamines